Table 2.
Participants with confirmed Streptococcus pneumoniae serotype 6B (strain BHN418) nasal carriage by microbiological culture from nasal wash
|
Placebo |
PCV13 |
|||
|---|---|---|---|---|
| S pneumoniae serotype 6B carriers | Proportion (95% CI) | S pneumoniae serotype 6B carriers | Proportion (95% CI) | |
| Day 2, CFU per naris | ||||
| 20 000 | 2/19 | 10·5% (1·3–33·1) | 0/21 | 0·0% (0·0–16·1) |
| 80 000 | 11/41 | 26·8% (14·2–42·9) | 4/33 | 12·1% (3·4–28·2) |
| 160 000 | 9/46 | 19·6% (9·4–33·9) | 4/44 | 9·1% (2·5–21·7) |
| Day 7, CFU per naris | ||||
| 20 000 | 1/19 | 5·3% (0·1–26.0) | 0/21 | 0·0% (0·0–16·1) |
| 80 000 | 8/41 | 19·5% (8·8–34·9) | 3/33 | 9·1% (1·9–24·3) |
| 160 000 | 9/46 | 19·6% (9·4–33·9) | 3/44 | 6·8% (1·4–18·7) |
| Day 14, CFU per naris | ||||
| 20 000 | 1/19 | 5·3% (0·1–26·0) | 0/21 | 0·0% (0·0–16·1) |
| 80 000 | 8/41 | 19·5% (8·8–34·9) | 1/33 | 3·0% (0·1–15·8) |
| 160 000 | 10/46 | 21·7% (10·9–36·4) | 3/44 | 6·8% (1·4–18·7) |
| All visits,*CFU per naris | ||||
| 20 000 | 2/19 | 10·5% (1·3–33·1) | 0/21 | 0·0% (0·0–16·1) |
| 80 000 | 12/41 | 29·3% (16·1–45·5) | 6/33 | 18·2% (7·0–35·5) |
| 160 000 | 16/46 | 34·8% (21·4–50·2) | 4/44 | 9·1% (2·5–21·7) |
Data are n/N, proportion (%), or 95% CI. Nasal wash samples were taken 2 days (visit E), 7 days (visit F) and 14 days (visit G) after bacterial inoculation. Differential carriage rates are categorised by inoculation dose and by randomisation allocation (intramuscular saline vs PCV13 28 days before bacterial inoculation). CFU=colony forming unit. PCV13=13-valent pneumococcal conjugate vaccine.
*
This row aggregates carriage data for individual participants across all three visits.